NASDAQ:HILS Hillstream BioPharma - HILS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.84 -0.07 (-8.13%) (As of 03/30/2023 02:10 PM ET) Add Compare Share Share Today's Range$0.82▼$0.9550-Day Range$0.43▼$1.8952-Week Range$0.30▼$2.78Volume51,730 shsAverage Volume3.21 million shsMarket Capitalization$9.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Hillstream BioPharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.99% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.78) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.30 out of 5 starsMedical Sector963rd out of 999 stocksPharmaceutical Preparations Industry470th out of 489 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Hillstream BioPharma. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.99% of the float of Hillstream BioPharma has been sold short.Short Interest Ratio / Days to CoverHillstream BioPharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hillstream BioPharma has recently increased by 25.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHillstream BioPharma does not currently pay a dividend.Dividend GrowthHillstream BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HILS. Previous Next 1.9 News and Social Media Coverage News SentimentHillstream BioPharma has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Hillstream BioPharma this week, compared to 0 articles on an average week.Search InterestOnly 10 people have searched for HILS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Hillstream BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hillstream BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders40.10% of the stock of Hillstream BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.77% of the stock of Hillstream BioPharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hillstream BioPharma are expected to grow in the coming year, from ($0.78) to ($0.44) per share.Price to Book Value per Share RatioHillstream BioPharma has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hillstream BioPharma (NASDAQ:HILS) StockHillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.Read More Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HILS Stock News HeadlinesMarch 28, 2023 | finance.yahoo.comHillstream BioPharma to Participate in Two Major Industry Conferences in April 2023March 23, 2023 | americanbankingnews.comDawson James Weighs in on Hillstream BioPharma, Inc.'s Q2 2023 Earnings (NASDAQ:HILS)March 30, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 28, 2023 | finance.yahoo.comHillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023February 15, 2023 | finance.yahoo.comHillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price RuleFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ETFebruary 13, 2023 | finance.yahoo.comHillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian CancerFebruary 10, 2023 | baystreet.caHillstream Nearly Doubles on Test ResultsMarch 30, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 10, 2023 | msn.comHillstream Soars on Promising HSB-1216 Data in Lung CancerFebruary 10, 2023 | finance.yahoo.comIn a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis InducerFebruary 8, 2023 | finance.yahoo.comHillstream BioPharma Announces Acceptance of Abstract at AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-functional Inhibitor for Solid Tumors & LeukemiasFebruary 6, 2023 | finance.yahoo.comHillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant CancersJanuary 31, 2023 | finance.yahoo.comWhy Are Hillstream BioPharma Shares Trading Over 100% Today?January 31, 2023 | finance.yahoo.comHillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 17, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023December 12, 2022 | finance.yahoo.comInsiders who purchased Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year recover some losses which currently stand at US$86kDecember 1, 2022 | finance.yahoo.comHillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated TargetsOctober 18, 2022 | finance.yahoo.comHillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR SymposiumOctober 6, 2022 | finance.yahoo.comHillstream BioPharma, Inc. to Present at Upcoming Investor ConferencesSeptember 21, 2022 | finance.yahoo.comHillstream BioPharma, Inc. (HILS)September 16, 2022 | benzinga.comHillstream BioPharma to Participate in the Fierce...September 14, 2022 | finance.yahoo.comHillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20July 8, 2022 | finance.yahoo.comHillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13July 4, 2022 | finance.yahoo.comA number of insiders bought Hillstream BioPharma, Inc. (NASDAQ:HILS) stock last year, which is great news for shareholdersJune 27, 2022 | finance.yahoo.comHillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer TreatmentsJune 13, 2022 | finance.yahoo.comWhy Hillstream BioPharma Shares Are Trading Higher Today?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HILS Company Calendar Today3/30/2023Next Earnings (Estimated)4/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HILS CUSIPN/A CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-105.78% Return on Assets-95.03% Debt Debt-to-Equity RatioN/A Current Ratio5.84 Quick Ratio5.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book1.74Miscellaneous Outstanding Shares11,510,000Free Float6,897,000Market Cap$9.62 million OptionableNot Optionable Beta3.74 Key ExecutivesMr. Randy D. Milby MBA (Age 69)Pres, Chairman & CEO Mr. Thomas P. Hess CPA (Age 59)MBA, Chief Financial Officer Key CompetitorsAdial PharmaceuticalsNASDAQ:ADILPulmatrixNASDAQ:PULMAthenexNASDAQ:ATNXAgile TherapeuticsNASDAQ:AGRXDiffusion PharmaceuticalsNASDAQ:DFFNView All CompetitorsInsidersRandy MilbyBought 500 shares on 6/17/2022Total: $390.00 ($0.78/share)Randy MilbyBought 1,000 shares on 6/6/2022Total: $690.00 ($0.69/share)Randy MilbyBought 1 shares on 6/1/2022Total: $0.94 ($0.94/share)Randy MilbyBought 1,000 shares on 5/25/2022Total: $790.00 ($0.79/share)Randy MilbyBought 1,000 shares on 5/20/2022Total: $920.00 ($0.92/share)View All Insider Transactions HILS Stock - Frequently Asked Questions Should I buy or sell Hillstream BioPharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HILS shares. View HILS analyst ratings or view top-rated stocks. How have HILS shares performed in 2023? Hillstream BioPharma's stock was trading at $0.3898 at the beginning of the year. Since then, HILS shares have increased by 114.5% and is now trading at $0.8360. View the best growth stocks for 2023 here. Are investors shorting Hillstream BioPharma? Hillstream BioPharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 116,100 shares, an increase of 25.1% from the February 28th total of 92,800 shares. Based on an average trading volume of 3,020,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 3.0% of the company's stock are short sold. View Hillstream BioPharma's Short Interest. When is Hillstream BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 3rd 2023. View our HILS earnings forecast. When did Hillstream BioPharma IPO? (HILS) raised $21 million in an IPO on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share. What is Hillstream BioPharma's stock symbol? Hillstream BioPharma trades on the NASDAQ under the ticker symbol "HILS." How do I buy shares of Hillstream BioPharma? Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Hillstream BioPharma's stock price today? One share of HILS stock can currently be purchased for approximately $0.84. How much money does Hillstream BioPharma make? Hillstream BioPharma (NASDAQ:HILS) has a market capitalization of $9.62 million. How can I contact Hillstream BioPharma? The official website for the company is www.hillstreambio.com. The company can be reached via phone at 908-955-3140 or via email at investorrelations@hillstreambio.com. This page (NASDAQ:HILS) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.